Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Stake Lessened by Thompson Siegel & Walmsley LLC

Thompson Siegel & Walmsley LLC lowered its holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERSFree Report) by 11.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 152,784 shares of the company’s stock after selling 20,000 shares during the period. Thompson Siegel & Walmsley LLC owned approximately 0.10% of Xeris Biopharma worth $518,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of XERS. R Squared Ltd purchased a new stake in shares of Xeris Biopharma in the fourth quarter valued at $42,000. Quantbot Technologies LP purchased a new stake in shares of Xeris Biopharma in the third quarter valued at $44,000. Raymond James Financial Inc. purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth $45,000. Sunpointe LLC purchased a new stake in shares of Xeris Biopharma during the fourth quarter worth $71,000. Finally, Janney Montgomery Scott LLC raised its holdings in shares of Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company’s stock worth $78,000 after acquiring an additional 5,500 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Price Performance

NASDAQ XERS opened at $4.82 on Friday. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $1.69 and a fifty-two week high of $4.90. The stock’s 50-day moving average is $3.68 and its two-hundred day moving average is $3.31. The firm has a market cap of $741.99 million, a P/E ratio of -10.71 and a beta of 2.32.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Jefferies Financial Group reiterated a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum increased their price objective on Xeris Biopharma from $5.00 to $6.50 and gave the stock a “buy” rating in a report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Piper Sandler reiterated a “neutral” rating and set a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Leerink Partners increased their price objective on Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $5.92.

Check Out Our Latest Stock Report on Xeris Biopharma

Xeris Biopharma Profile

(Free Report)

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Featured Articles

Want to see what other hedge funds are holding XERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xeris Biopharma Holdings, Inc. (NASDAQ:XERSFree Report).

Institutional Ownership by Quarter for Xeris Biopharma (NASDAQ:XERS)

Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.